Home › Companies › Amylyx Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Amylyx Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2025-2026
Explore Amylyx Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Amylyx Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: George Mclean Milne Jr., Ph.D. | 76,937,972 | -- | -- | 14,108,630 | 11,029,810 | Majority: yes |
| Elect Director: Paul Fonteyne | 86,275,670 | -- | -- | 4,770,932 | 11,029,810 | Majority: yes |
| Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending D | 102,036,295 | 34,484 | 5,633 | -- | 0 | Majority: yes |
| Proposal 3: Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers | 77,534,824 | 13,490,653 | 21,125 | -- | 11,029,810 | Majority: yes |
Source: Amylyx Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-04 — read the filing on EDGAR.
Each item below shows how the 216 asset managers that disclosed a Amylyx Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Amylyx Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named exe”): 77,534,824 for, 13,490,653 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 111,026,477 outstanding shares: 70% for, 12% against (82% of the company cast a for/against vote).
The 216 asset managers below cast 86% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 34,122,453 | 0 | 0 | 0 | For |
| BlackRock | 7,533,687 | 11,736 | 0 | 0 | For |
| Vanguard | 5,741,251 | 16,251 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 5,695,994 | 0 | 0 | 0 | For |
| Commodore Capital LP | 5,650,000 | 0 | 0 | 0 | For |
| Janus Henderson | 4,609,500 | 0 | 0 | 0 | For |
| Saturn V Capital Management LP | 4,259,868 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 3,146,028 | 0 | 0 | Against |
| GREAT POINT PARTNERS LLC | 3,127,204 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 3,092,866 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0 | 2,600,516 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 0 | 2,536,555 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 2,207,533 | 0 | 0 | 0 | For |
| State Street | 1,917,975 | 25,924 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,512,444 | 0 | 0 | 0 | For |
| 683 Capital Management, LLC | 1,497,683 | 0 | 0 | 0 | For |
| Charles Schwab | 1,431,440 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 1,364,236 | 0 | 0 | Against |
| Goldman Sachs | 1,251,510 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 1,084,738 | 0 | 0 | 0 | For |
| Woodline Partners LP | 845,800 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 841,275 | 0 | 0 | 0 | For |
| Northern Trust | 565,033 | 24,098 | 0 | 0 | For |
| JUPITER ASSET MANAGEMENT LTD | 0 | 571,559 | 0 | 0 | Against |
| Nantahala Capital Management, LLC | 535,684 | 0 | 0 | 0 | For |
Showing the 25 largest of 216 asset managers. See all 216 in the interactive database.
Combines 3 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Amylyx Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: George Mclean Milne Jr., Ph.D.”): 76,937,972 for, 14,108,630 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 111,026,477 outstanding shares: 69% for, 13% withheld (82% of the company cast a for/withheld vote).
The 59 asset managers below cast 100% of the shares they voted on this item FOR (31,262,472 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 17,590,784 | 0 | 0 | 0 | For |
| Vanguard | 5,028,218 | 0 | 10,936 | 0 | For |
| BlackRock | 4,450,090 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,512,444 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 1,364,236 | 0 | Abstain |
| Charles Schwab | 714,213 | 0 | 0 | 0 | For |
| State Street | 396,719 | 0 | 389 | 0 | For |
| Prudential/PGIM | 373,490 | 0 | 2,560 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 282,418 | 0 | Abstain |
| Equitable | 179,733 | 0 | 49,500 | 0 | For |
| First Trust | 0 | 0 | 228,569 | 0 | Abstain |
| Bridge Builder Trust | 219,001 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 189,605 | 0 | Abstain |
| TIAA | 175,343 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 136,216 | 0 | Abstain |
| Federated Hermes | 127,981 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 89,983 | 0 | Abstain |
| JPMorgan | 85,210 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 59,414 | 0 | Abstain |
| Northern Trust | 0 | 0 | 58,983 | 0 | Abstain |
| Lincoln Financial | 58,400 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,999 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,098 | 0 | 47,259 | 0 | Abstain |
| Brighthouse | 14,699 | 0 | 32,428 | 0 | Abstain |
| Global X | 42,973 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Amylyx Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Paul Fonteyne”): 86,275,670 for, 4,770,932 withheld, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 111,026,477 outstanding shares: 78% for, 4% withheld (82% of the company cast a for/withheld vote).
The 59 asset managers below cast 100% of the shares they voted on this item FOR (31,990,479 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 17,567,874 | 0 | 22,910 | 0 | For |
| Vanguard | 5,031,831 | 0 | 7,323 | 0 | For |
| BlackRock | 4,104,535 | 0 | 345,555 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,512,444 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 1,364,236 | 0 | Abstain |
| Charles Schwab | 714,213 | 0 | 0 | 0 | For |
| State Street | 396,995 | 0 | 113 | 0 | For |
| Prudential/PGIM | 373,490 | 0 | 2,560 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 282,418 | 0 | 0 | 0 | For |
| Equitable | 229,233 | 0 | 0 | 0 | For |
| First Trust | 228,569 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 219,001 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 189,605 | 0 | Abstain |
| TIAA | 175,343 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 136,216 | 0 | 0 | 0 | For |
| Federated Hermes | 127,981 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 89,983 | 0 | 0 | 0 | For |
| JPMorgan | 85,210 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 59,414 | 0 | 0 | 0 | For |
| Northern Trust | 58,983 | 0 | 0 | 0 | For |
| Lincoln Financial | 58,400 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,999 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 49,357 | 0 | 0 | 0 | For |
| Brighthouse | 43,975 | 0 | 3,152 | 0 | For |
| Global X | 42,973 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
99.9% Majority: yes · of votes cast
Amylyx Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public acco”): 102,036,295 for, 34,484 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 111,026,477 outstanding shares: 92% for, 0.1% against (92% of the company cast a for/against vote).
The 59 asset managers below cast 100% of the shares they voted on this item FOR (34,013,791 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 17,590,784 | 0 | 0 | 0 | For |
| Vanguard | 5,039,154 | 0 | 0 | 0 | For |
| BlackRock | 4,450,090 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,512,444 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,364,236 | 0 | 0 | 0 | For |
| Charles Schwab | 714,213 | 0 | 0 | 0 | For |
| State Street | 397,108 | 0 | 0 | 0 | For |
| Prudential/PGIM | 376,050 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 282,418 | 0 | 0 | 0 | For |
| Equitable | 229,233 | 0 | 0 | 0 | For |
| First Trust | 228,569 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 219,001 | 0 | 0 | 0 | For |
| Dimensional | 189,605 | 0 | 0 | 0 | For |
| TIAA | 175,343 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 136,216 | 0 | 0 | 0 | For |
| Federated Hermes | 127,981 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 89,983 | 0 | 0 | 0 | For |
| JPMorgan | 85,210 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 59,414 | 0 | 0 | 0 | For |
| Northern Trust | 58,983 | 0 | 0 | 0 | For |
| Lincoln Financial | 58,400 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,999 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 49,357 | 0 | 0 | 0 | For |
| Brighthouse | 43,975 | 0 | 3,152 | 0 | For |
| Global X | 42,973 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Ranked by the number of Amylyx Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 111,026,477 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 30.73% |
| 2 | BlackRock | 6.80% |
| 3 | Vanguard | 5.19% |
| 4 | PERCEPTIVE ADVISORS LLC | 5.13% |
| 5 | Commodore Capital LP | 5.09% |
| 6 | Janus Henderson | 4.15% |
| 7 | Saturn V Capital Management LP | 3.84% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.83% |
| 9 | GREAT POINT PARTNERS LLC | 2.82% |
| 10 | First Light Asset Management, LLC | 2.79% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.98% | 13F |
| BlackRock | 7.95% | 13F |
| TCG Crossover GP II, LLC | 5.62% | 13G |
| Vanguard Group | 5.23% | 13F |
| Goldman Sachs | 2.37% | 13F |
| State Street | 2.13% | 13F |
| Morgan Stanley | 2.13% | 13F |
| Franklin Templeton | 2.04% | 13F |
| Geode Capital | 1.99% | 13F |
| Dimensional Fund Advisors | 0.81% | 13F |
Percentages above are of 111,026,477 shares outstanding, as reported by Amylyx Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Amylyx Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Amylyx Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 216 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,051 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 85% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Amylyx Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-04.
Amylyx Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2025-2026 (this page).